<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>AMA Publishing Group: Percutaneous Coronary Intervention Topic Collection</title>
    <link>http://pubs.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Wed, 01 May 2013 00:00:00 GMT</pubDate>
    <lastBuildDate>Wed, 08 May 2013 22:45:36 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@pubs.jamanetwork.com</managingEditor>
    <webMaster>webmaster@pubs.jamanetwork.com</webMaster>
    <item>
      <title>Study Ignites Debate on New Anticoagulant</title>
      <link>http://pubs.jamanetwork.com/article.aspx?articleID=1682936</link>
      <pubDate>Wed, 01 May 2013 00:00:00 GMT</pubDate>
      <author>Mitka M. </author>
      <description>&lt;span class="paragraphSection"&gt;San Francisco— Researchers claim that an experimental anticlotting drug that failed to demonstrate benefit in 2 previous studies showed positive results in a new study. They said the experimental drug, cangrelor, may offer another option for reducing periprocedural complications from percutaneous coronary intervention (PCI). But others are not so sure.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">17</prism:number>
      <prism:startingPage xmlns:prism="prism">1763</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">1764</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.3857</prism:doi>
      <guid>http://pubs.jamanetwork.com/article.aspx?articleID=1682936</guid>
    </item>
  </channel>
</rss>